The Australian MPS VI Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
MPS VI is an inherited disorder that encompasses a wide spectrum of severity. Physical symptoms may include bone and joint malformation, hearing and vision problems, and heart and breathing difficulties. The rate of disease progression and age of onset vary considerably, even in affected siblings: in some, it may be rapid with diagnosis in the first few years of life; in others it may be relatively slow and diagnosis may not occur until the third or fourth decade. Generally, if clinical symptoms are apparent early in life it is more likely that disease progress will be more rapid. MPS VI is also known as Maroteaux-Lamy syndrome. Mucopolysaccharides are used by the cells to build connective tissues in the body, such as skin, muscle, cartilage and bone. They also help with many other cellular functions, including growth control, organ development and signalling between cells. n people with an MPS disorder one of the lysosomal enzymes that is needed to degrade mucopolysaccharides is either missing or is present at levels that do not allow the recycling process to work properly.
It has been estimated that in Australia about 1 in 248,372 births are affected by MPS VI. The incidence of all MPS disorders combined (of which 11 are currently recognised) is estimated to be 1 in 25,000 births.
The growth in the number of products in the preliminary and advanced stages of R&D along with the focus on treatment of rare diseases is anticipated to drive the growth in the market at a considerably fast rate. With the approval of the elosulfase alpha (VIMIZIM), the market is expected to be boosted several products currently in the pipeline of various companies can be anticipated to undergo regulatory approvals for the marketing, if they have favourable clinical trials results. However, rising treatment costs and a lack of awareness among patients and physicians about MPS VI are among the major factors acting as restraints, and will continue to pose a challenge to the MPS VI treatment market in the forecast period.